Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Published:2018-12-14 Issue:98 Volume:9 Page:37173-37184
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Sinha Sutapa¹,Boysen Justin C.¹,Chaffee Kari G.²,Kabat Brian F.²,Slager Susan L.²,Parikh Sameer A.¹,Secreto Charla R.¹,Call Tim¹,Shanafelt Tait D.³,Leis Jose F.⁴,Warner Steven L.⁵,Bearss David J.⁵,Ghosh Asish K.⁶,Kay Neil E.¹

Affiliation:

1. Division of Hematology and Mayo Clinic, Rochester, MN, USA

2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

3. Department of Medicine-Hematology, Stanford School of Medicine, Stanford, CA, USA

4. Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA

5. Tolero Pharmaceuticals, Inc., Lehi, UT, USA

6. Stephenson Cancer Center and Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications;British Journal of Cancer;2024-06-17

2. Disrupting EGFR–HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome;International Journal of Molecular Sciences;2024-05-29

3. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications;Frontiers in Oncology;2024-04-03

4. In Vitro and Reactive Metabolites Investigation of Metabolic Profiling of Tyrosine Kinase Inhibitors Dubermatinib in HLMs by LC–MS/MS;Separations;2023-06-13

5. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL;Blood Advances;2022-09-26